MeSH D055623 - actinic keratosis
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| 3M | Imiquimod | Zartra |  | 1998-09-18 |  |  |
| Almirall | Tirbanibulin | Klisyri |  | 2021-07-16 |  |  |
| Apotex | Imiquimod | Imiquimod |  | 2012-04-06 |  |  |
| Bausch Health Companies | Imiquimod | Aldara | 2024-04-01 | 1997-02-27 |  |  |
| Imiquimod | Zyclara | 2029-08-18 | 2010-03-25 |  |  | |
| Biofrontera | Aminolevulinic acid | Ameluz | 2028-02-07 | 2016-05-10 | $21.5 M | Q3/20-Q1/22 |
| Cosette Pharmaceuticals | Imiquimod | Imiquimod |  | 2011-04-18 |  |  |
| Encube Ethicals | Imiquimod | Imiquimod |  | 2011-02-28 |  |  |
| Fougera Pharmaceuticals | Imiquimod | Imiquimod |  | 2010-02-25 |  |  |
| Glenmark Pharmaceuticals | Imiquimod | Imiquimod |  | 2012-03-06 |  |  |
| LEO Pharma | Ingenol mebutate | Picato | 2026-12-18 | 2012-01-23 |  |  |
1
2
>
Clinical Trials
Historical Success Rate
Phase 1
83%15/18
Phase 2
30%7/23
Phase 3
83%15/18
Approved: 7Overall Success rate: 21%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use